Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Healthtrust
Cerilliant
Harvard Business School
Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Fuji
Fish and Richardson
Cantor Fitzgerald

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,808,716

« Back to Dashboard

Which drugs does patent 8,808,716 protect, and when does it expire?

Patent 8,808,716 protects FABIOR and is included in one NDA.

This patent has nineteen patent family members in thirteen countries.
Summary for Patent: 8,808,716
Title:Topical foam composition
Abstract: The present invention relates to a novel oil in water emulsion aerosol foam composition containing an active agent for the treatment of various chronic and acute skin conditions, particularly acne and psoriasis; and processes for preparing the emulsion aerosol foam compositions. In particular, the present invention relates to oil in water emulsion aerosol foam compositions containing a retinoid in the oil phase.
Inventor(s): Loupenok; Leon (Rowville, AU)
Assignee: Stiefel Research Australia Pty Ltd (Rowville, Victoria, AU)
Application Number:13/553,849
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 8,808,716

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mayne Pharma FABIOR tazarotene AEROSOL, FOAM;TOPICAL 202428-001 May 11, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,808,716

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2012518662 ➤ Try a Free Trial
Japan 6130992 ➤ Try a Free Trial
Israel 214520 ➤ Try a Free Trial
European Patent Office 2400951 ➤ Try a Free Trial
Eurasian Patent Organization 020844 ➤ Try a Free Trial
China 102438590 ➤ Try a Free Trial
Eurasian Patent Organization 201171079 ➤ Try a Free Trial
Canada 2753497 ➤ Try a Free Trial
Brazil PI1008037 ➤ Try a Free Trial
Australia 2010217190 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
McKinsey
US Army
Chubb
Express Scripts
Merck
Daiichi Sankyo
Harvard Business School
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot